Changing Concepts in the Treatment of Advanced Seminomatous Tumors

Abstract

The treatment of patients with advanced seminomatous tumors represents a challenge for the medical and urological oncologists. In contrast to the reported excellent results of radiotherapy in the treatment of patients with clinical stages I and II disease, the survival rate for those with advanced seminomatous disease is only .apprx. 40%. Six consecutive patients with metastatic seminomas were treated with systemic chemotherapy; all achieved a complete response. The combination of vincristine, cis-platinum, bleomycin and prednisone was used in 4 patients; an excellent tolerance was observed even in patients with previous radiation therapy. Two other patients who had radiation therapy to the mediastinum were treated with VP-16 [etoposide] and cis-platinum; again a complete response was observed. However, a significant potentiation of myelosuppressive effect of VP-16 was observed in the previously radiated patients. In view of the observed sensitivity of seminomatous tumors, it appears that all patients who present initially with metastatic or bulky retroperitoneal disease should be treated with multiple drug chemotherapy and cytoreductive surgery similar to the treatment modalities used for nonseminomatous germ cell tumors. Radiation therapy for patients with this stage of the disease seems to be ineffective and may compromise the benefits of aggressive chemotherapy.